[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Kurzidem M, Seidensticker P, Rassweiler J: Renal chemoembolization with mitomycin c/Ethibloc: pharmacokinetics and efficacy in an animal model. J Endourol; 2002 Sep;16(7):515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Arterial embolization can be an alternative treatment for kidney malignancy.
  • MATERIALS AND METHODS: In 32 rats with implanted Yoshida sarcoma, nephrectomy was carried out 15, 30, 60, or 90 minutes after chemoembolization (1 mg v 2 mg of MMC/mL of Ethibloc) or chemoperfusion (1 mg of MMC/mL of NaCl) of the tumor-bearing kidney.
  • The MMC tissue concentration was measured in the kidney specimens.
  • We compared the survival time of rats with Yoshida sarcoma after chemoembolization (N = 15), chemoperfusion (N = 18), embolization (N = 18), nephrectomy (N = 21), and no treatment (N = 25).
  • RESULTS: The MMC tissue concentration in the rat model was much higher after chemoembolization than after chemoperfusion for at least 1.5 hours.
  • CONCLUSION: Chemoembolization produces persistently high tissue concentrations of MMC and avoids toxic peak serum levels.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. DIATRIZOATE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12396445.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Combinations; 0 / Fatty Acids; 0 / Propylene Glycols; 0 / Sclerosing Solutions; 117-96-4 / Diatrizoate; 50SG953SK6 / Mitomycin; 9010-66-6 / Zein; 91196-33-7 / alcoholic prolamine solution
  •  go-up   go-down


2. Sato H, Hori K, Sugiyama K, Tanda S, Sato Y: [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments]. Gan To Kagaku Ryoho; 2000 Jul;27(8):1191-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments].
  • Tumor tissue is composed of cancer cells (parenchyma) and tumor vessels (interstitium).
  • This would be a certain cause of insufficient drug delivery to tumor tissues.
  • Among the experimental evidence using Yoshida Sarcoma and Ascites Hepatomas, functional differences in microcirculation between tumor and normal tissues were found by Suzuki et al. (1977).
  • Under hypertensive state induced by the continuous infusion of angiotensin II, tumor blood flow increased remarkably, while there was no change or decrease in blood flow in normal tissues such as the brain, bone marrow, liver and kidney.
  • Augmentation of the anti-tumor effects of angiotensin II-induced hypertension chemotherapy (IHC) for advanced gastric carcinoma was revealed in two randomized controlled trials (RCT-1 & 2) of collaborative study groups in Japan.
  • It is very important for exact evaluation after chemotherapy to understand or estimate the pathohistological changes in the tumor and its degenerated or repaired tissues, which present various clinical images.
  • IHC with smaller DI could lead to a reduction in the accumulation of toxicities of anti-cancer drugs in the host.
  • In conclusion, IHC might be applied to all kinds of tumors to enhance the chemotherapeutic effects through selective increase of drug delivery to tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Delivery Systems / methods. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Doxorubicin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Microcirculation. Mitomycin / administration & dosage. Rats

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10945016.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  • [Number-of-references] 77
  •  go-up   go-down


3. Hori K, Furumoto S, Kubota K: Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth. Cancer Sci; 2008 Jul;99(7):1485-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify the therapeutic significance of interrupting tumor blood flow after irradiation, we investigated X-irradiation-induced changes in hemodynamic parameters (blood flow, extravasation and washout of fluorescein isothiocyanate-dextran, and interstitial fluid pressure) in a variant of Yoshida sarcoma, LY80.
  • Tumors in anesthetized male Donryu rats received local irradiation (10 Gy).
  • At all times evaluated after irradiation, AC7700 completely stopped tumor blood flow.
  • This therapeutic combination and timing may have important benefits, even in tumors with low sensitivity to either treatment alone, because the effect was considerably greater than additive.
  • [MeSH-minor] Animals. Cell Proliferation / radiation effects. Combined Modality Therapy. Hemodynamics / radiation effects. Male. Rats. Regional Blood Flow / drug effects

  • Hazardous Substances Data Bank. L-SERINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452559.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC 7700; 452VLY9402 / Serine
  •  go-up   go-down


Advertisement
4. Koceva-Chyła A, Kochman A, Głebska J, Gwoździnski K, Jóźwiak Z, Metodiewa D: Tempicol-3, a novel piperidine-N-oxide stable radical and antioxidant, with low toxicity acts as apoptosis inducer and cell proliferation modifier of Yoshida Sarcoma cells in vivo. Anticancer Res; 2000 Nov-Dec;20(6B):4611-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tempicol-3, a novel piperidine-N-oxide stable radical and antioxidant, with low toxicity acts as apoptosis inducer and cell proliferation modifier of Yoshida Sarcoma cells in vivo.
  • The ability of Tempicol-3 to act as an antitumor agent in vivo was also investigated in a pharmacological test, using rats bearing 3-day old Yoshida Sarcoma (promotion phase of the disease).
  • We have also observed that lowtoxic Tempicol-3, at m.e.d. (minimal effective dose) suppressed tumorigenesis, acting as a cell proliferation modifier and apoptosis inducer in vivo.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antioxidants / pharmacology. Apoptosis / drug effects. Cell Division / drug effects. Sarcoma, Yoshida / drug therapy
  • [MeSH-minor] 3T3 Cells / drug effects. Animals. Ascites / drug therapy. Ascites / pathology. Cyclic N-Oxides / chemistry. Cyclic N-Oxides / pharmacology. Drug Screening Assays, Antitumor. Mice. Piperidines / pharmacology. Rats. Rats, Inbred BUF. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205311.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Cyclic N-Oxides; 0 / Piperidines; 0 / tempicol 3; 14691-89-5 / tempace; VQN7359ICQ / TEMPO
  •  go-up   go-down


5. Luboldt W, Pinkert J, Matzky C, Wunderlich G, Kotzerke J: Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr Drug Deliv; 2009 Jul;6(3):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Success of selective drug therapies depends on the drug's depot time in the target to treat.
  • Depot time is currently being prolonged, using drug-eluting beads or microspheres for selective internal radiation therapy.
  • The purpose of this study was to establish a model for investigating the depot time of particles injected into tumors in relation to tumor vascularization and particle size.
  • MATERIALS AND METHODS: An animal model with two different vascularized tumors (Walker Carcinoma 256 (hypervascularized) and Yoshida Sarcoma (hypovascularized)) was used.
  • Measurements were adjusted for decay times and then compared.
  • CONCLUSIONS: Particle stay time, biodistribution, and stability can be easily monitored as shown in this animal model.
  • Prolonged retention is independent of vascularization and particle size and appears to be sufficient for therapy.
  • [MeSH-minor] Animals. Carcinoma 256, Walker / blood supply. Carcinoma 256, Walker / metabolism. Epinephrine / pharmacology. Female. Humans. Injections, Intralesional. Kidney / metabolism. Liver / metabolism. Lung / metabolism. Radioisotopes / chemistry. Rats. Rats, Wistar. Rhenium / chemistry. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / metabolism. Serum Albumin / chemistry. Spleen / metabolism. Sulfur / chemistry. Tissue Distribution / drug effects

  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. Sulfur, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604139.001).
  • [ISSN] 1567-2018
  • [Journal-full-title] Current drug delivery
  • [ISO-abbreviation] Curr Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Serum Albumin; 0 / rhenium sulfur colloid; 70FD1KFU70 / Sulfur; 7440-15-5 / Rhenium; YKH834O4BH / Epinephrine
  •  go-up   go-down


6. Rassweiler J, Prager P, Haferkamp A, Alken P, Kauffmann GW, Richter G: Transarterial nephrectomy: the current status of experimental and clinical studies. J Endourol; 2008 Apr;22(4):767-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For several years, minimally invasive alternatives have been developed such as laparoscopic nephrectomy or transarterial renal ablation.
  • MATERIALS AND METHODS: Based on own in vitro studies, the principle of capillary embolization with occlusion of the entire arterial system up to the capillaries by a precipitating corn protein (Ethibloc) has been developed in animal studies (i.e., rat and canine kidney model).
  • Further studies using the model of unilateral transarterial implantation of Yoshida-sarcoma cells compared capillary chemoembolization using Ethibloc/mitomycin C (MMC) versus chemoperfusion and capillary embolization.
  • RESULTS: Capillary embolization proved to be significantly superior to a central (i.e., ligation of renal artery) or peripheral type of occlusion resulting in complete coagulation necrosis of the normal rat and canine kidney with reduction of the elevated blood pressure, similar to nephrectomy in the model of renal hypertension.
  • In the highly aggressive Yoshida-sarcoma model, capillary chemoembolization yielded an 80% complete response rate compared to only 75% after capillary embolization and 70% after chemoperfusion.
  • Clinical studies included 68 preoperatively as well as 62 palliatively embolized patients with renal cell carcinoma.
  • The procedure was relatively well tolerated and usually associated with a mild postembolization syndrome.
  • Because of the local ablative efficiency, it may still represent a minimally invasive option in advanced stages of renal carcinoma (i.e., in combination with immunochemotherapy or targeted therapy).

  • Hazardous Substances Data Bank. DIATRIZOATE .
  • Hazardous Substances Data Bank. N-NITROSODIMETHYLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366320.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Fatty Acids; 0 / Propylene Glycols; 0 / Sclerosing Solutions; 117-96-4 / Diatrizoate; 9010-66-6 / Zein; 91196-33-7 / alcoholic prolamine solution; M43H21IO8R / Dimethylnitrosamine
  •  go-up   go-down


7. Hori K, Saito S, Kubota K: A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer; 2002 May 20;86(10):1604-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
  • In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and methylcholanthrene-induced primary tumours, to demonstrate that a novel water-soluble combretastatin A-4 derivative, AC7700, abruptly and irreversibly stopped tumour blood flow.
  • In a model of cancer chemotherapy against metastases, LY80 cells (2x10(6)) were injected into the lateral tail vein, and AC7700 at 10 mg x kg(-1) was injected i.v. five times at intervals of 2 days, starting on day 7 after tumour cell injection.
  • The change in tumour blood flow and the therapeutic effect of AC7700 on microtumours were observed directly by using Sato lung carcinoma implanted in a rat transparent chamber.
  • AC7700 caused a marked decrease in the tumour blood flow of all LY80 tumours developing in various tissues and organs and growth of all tumours including lymph node metastases and microtumours was inhibited.
  • These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases.
  • We conclude that tumour blood flow stanching induced by AC7700 may become an effective therapeutic strategy for all cancers, including refractory cancers because the therapeutic effect is independent of tumour site and specific type of cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma / drug therapy. Lung Neoplasms / drug therapy. Prodrugs / therapeutic use. Sarcoma, Yoshida / drug therapy. Serine / analogs & derivatives. Serine / therapeutic use. Vasoconstrictor Agents / therapeutic use
  • [MeSH-minor] Animals. Drug Screening Assays, Antitumor. Heart Neoplasms / blood supply. Heart Neoplasms / drug therapy. Kidney Neoplasms / blood supply. Kidney Neoplasms / drug therapy. Liver Neoplasms, Experimental / blood supply. Liver Neoplasms, Experimental / drug therapy. Lymphatic Metastasis. Male. Neoplasm Transplantation. Organ Specificity. Rats. Regional Blood Flow / drug effects. Skin Window Technique. Stomach Neoplasms / blood supply. Stomach Neoplasms / drug therapy. Tumor Cells, Cultured / transplantation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. L-SERINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] comCopyright 2002 Cancer Research UK
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):1016-25 [10551333.001]
  • [Cites] Circ Res. 1964 Feb;14:164-87 [14118761.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1318-27 [10604728.001]
  • [Cites] Jpn J Cancer Res. 1999 Dec;90(12):1387-95 [10665658.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1833-43 [10974632.001]
  • [Cites] Biochem Pharmacol. 2001 Feb 1;61(3):253-70 [11172729.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):290-5 [11161390.001]
  • [Cites] Med Sci Monit. 2001 Jan-Feb;7(1):26-33 [11208488.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Pathol. 1975 Jun;116(2):65-72 [168332.001]
  • [Cites] Gan. 1979 Jun;70(3):383-4 [467900.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Feb;19(2):271-5 [6681772.001]
  • [Cites] J Natl Cancer Inst. 1989 Feb 1;81(3):216-20 [2911084.001]
  • [Cites] Experientia. 1989 Feb 15;45(2):209-11 [2920809.001]
  • [Cites] J Natl Cancer Inst. 1989 Jul 5;81(13):1005-13 [2733044.001]
  • [Cites] Acta Anat (Basel). 1989;136(1):27-33 [2816252.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Oct;25(10):1419-24 [2591434.001]
  • [Cites] Jpn J Cancer Res. 1990 Mar;81(3):279-88 [1693611.001]
  • [Cites] Eur J Cancer. 1991;27(4):482-7 [1827725.001]
  • [Cites] Jpn J Cancer Res. 1991 Nov;82(11):1309-16 [1752787.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1320-4 [8343277.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):870-2 [8313372.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1163-8 [7779706.001]
  • [Cites] Int J Cancer. 1996 Jan 26;65(3):360-4 [8575858.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S86-8 [8763854.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1829-34 [9157969.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] J Med Chem. 1998 Jul 30;41(16):3022-32 [9685242.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):895-8 [9845117.001]
  • [Cites] Bioorg Med Chem Lett. 1998 Nov 17;8(22):3153-8 [9873694.001]
  • [Cites] Bioorg Med Chem Lett. 1998 Dec 1;8(23):3371-4 [9873736.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1626-34 [10197639.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):189-95 [10226542.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):1026-38 [10551334.001]
  • (PMID = 12085211.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / AC 7700; 0 / Antineoplastic Agents, Phytogenic; 0 / Prodrugs; 0 / Vasoconstrictor Agents; 452VLY9402 / Serine
  • [Other-IDs] NLM/ PMC2746587
  •  go-up   go-down


8. Yoshida S, Kaibara A, Ishibashi N, Shirouzu K: Glutamine supplementation in cancer patients. Nutrition; 2001 Sep;17(9):766-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Three series of studies investigated whether 1) glutamine deficiency occurs in tumor-bearing rats, 2) glutamine supplementation improves protein metabolism during chemotherapy in tumor-bearing rats, and 3) oral glutamine supplement improves systemic immune and gut-barrier function in patients with esophageal cancer receiving radiochemotherapy.
  • METHODS: In the animal studies, AH109A hepatoma cells or Yoshida sarcoma cells were inoculated into male Donryu rats to induce tumors.
  • Glutamine-supplemented total parenteral nutrition reduced whole-body protein breakdown rate during chemotherapy in tumor-bearing rats.
  • CONCLUSIONS: Glutamine depletion in host tissues occurs in tumor-bearing rats.
  • [MeSH-major] Cachexia / therapy. Esophageal Neoplasms / therapy. Glutamine / administration & dosage. Glutamine / metabolism. Proteins / metabolism
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carbon Isotopes. Case-Control Studies. Combined Modality Therapy. Dietary Supplements. Disease Models, Animal. Humans. Male. Parenteral Nutrition, Total. Rats

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Glutamine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11527675.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / Proteins; 0RH81L854J / Glutamine
  •  go-up   go-down






Advertisement